Mount Sinai has joined the Clinical Proteomic Tumor Analysis Consortium (CPTAC), a national initiative aimed at advancing cancer treatment by integrating proteogenomics—analyzing the proteins encoded by cancer genes. Led by Pei Wang, PhD, Professor of Genetics and Genomic Sciences, and Avi Ma'ayan, PhD, Professor of Pharmacological Sciences, the program focuses on understanding how cancer-related proteins influence tumor progression and treatment response. With a $4.2 million grant from the National Cancer Institute, Mount Sinai's team will lead data analysis efforts to improve precision medicine, offering insights that go beyond genomics to create more personalized cancer therapies.